Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
University of Pavia and IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
Clin Exp Rheumatol. 2020 Nov-Dec;38(6):1046-1055. Epub 2020 Nov 17.
Psoriatic arthritis (PsA) is an inflammatory arthritis belonging to spondyloarthritides (SpA), a group of rheumatologic diseases characterised bya wide spectrum of different clinical manifestations that tend to associate with various comorbidities and that may significantly compromise the quality of life of patients. Nowadays, it is well known how PsA may manifest in different clinical domains, in particular peripheral articular and periarticular involvement, axial involvement, skin and nail psoriasis. Moreover, the majority of patients with PsA develop comorbidities such as inflammatory bowel diseases, uveitis, but also cardiovascular diseases, psychiatric or pulmonary pathologies. The therapeutical armamentarium of PsA has been enriched during the last years, in relation to an advance in the knowledge of the immunological mechanisms at the basis of the disease; in particular, the future frontier of "personalised medicine" could lead to a further improvement in the quality of care of this group of patients. In this paper we review the literature on PsA of 2019 (Medline search of articles published from 1st January 2019 to 31st December 2019).
银屑病关节炎(PsA)是一种炎症性关节炎,属于脊柱关节炎(SpA),这是一组风湿性疾病,具有广泛的不同临床表现,往往与各种合并症相关,并可能严重影响患者的生活质量。如今,人们已经很清楚 PsA 可能在不同的临床领域表现出来,特别是外周关节和关节周围受累、轴性受累、皮肤和指甲银屑病。此外,大多数 PsA 患者会出现合并症,如炎症性肠病、葡萄膜炎,还会出现心血管疾病、精神或肺部疾病。近年来,随着对疾病基础免疫机制的认识不断提高,PsA 的治疗方法也得到了丰富。特别是,“个性化医疗”的未来前沿可能会进一步提高这组患者的护理质量。本文回顾了 2019 年有关 PsA 的文献(对 2019 年 1 月 1 日至 12 月 31 日期间发表的文章进行 Medline 搜索)。